Department of Medical Laboratory Science, College of Health Sciences, Woldia University, Woldia, Ethiopia.
Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
PLoS One. 2024 Aug 13;19(8):e0308946. doi: 10.1371/journal.pone.0308946. eCollection 2024.
Antimicrobial-resistant (AMR) bacterial infection is a significant global threat to the healthcare systems. Pseudomonas aeruginosa, the leading infectious agent in the healthcare setting is now one of the major threats due to AMR. A comprehensive understanding of the magnitude of AMR, particularly highly public health important pathogens such as P. aeruginosa, is necessary for the management of infections based on local information.
This systematic review and meta-analysis aimed to determine the country-wide AMR of P. aeruginosa.
Systematic searches were performed to retrieve articles from PubMed, Scopus, Web of Science, ScienceDirect electronic databases, Google Scholar search engine, and repository registrars from 2015 to 31st December 2023. Twenty-three studies that provided important data on AMR in P. aeruginosa were systematically reviewed and analyzed to determine the country-wide magnitude of P. aeruginosa AMR profile from healthcare-associated infections. AMR of P. aeruginosa to 10 different antibiotics were extracted separately into Microsoft Excel and analyzed using STATA 17.0. Cohen's kappa was computed to determine the agreement between reviewers, the Inverse of variance (I2) was used to evaluate heterogeneity across studies, and Egger's test to identify publication bias. A random effect model was used to determine the pooled resistance to each antibiotic. Subgroup analysis was performed by infection type and year of publication.
This systematic review and meta-analysis revealed that the pooled prevalence of P. aeruginosa in clinical specimens associated with HAI was 4.38%(95%CI: 3.00-5.76). The pooled prevalence of AMR in P. aeruginosa for different antibiotics varies, ranging from 20.9% (95%CI: 6.2-35.8) for amikacin to 98.72% (95%CI: 96.39-101.4) for ceftriaxone. The pooled resistance was higher for ceftriaxone (98.72%), Trimethoprim-sulfamethoxazole (75.41), and amoxicillin-clavulanic acid (91.2). In contrast relatively lower AMR were observed for amikacin (20.9%) and meropenem (28.64%). The pooled multi-drug resistance (MDR) in P. aeruginosa was 80.5% (95%CI: 66.25-93.84). Upon subgroup analysis by infection types and year of publication, P. aeruginosa isolated from healthcare-associated infections exhibited higher resistance to ceftazidime (94.72%) compared to isolates from mixed types of healthcare-associated infections (70.84%) and surgical site infections (57.84%). Antimicrobial resistance in gentamicin was higher during the periods of 2018-2020 (73.96%), while comparatively lower during 2021-2023 (42.69%) and 2015-2017 (29.82%).
Significantly high AMR and MDR were observed from this systematic review and meta-analysis. AMR obtained from this systematic review and meta-analysis urges the need for improved infection control, antimicrobial stewardship practices, and strengthened surveillance systems to control the spread of AMR and ensure effective treatment of P. aeruginosa infections.
This systematic review and meta-analysis was registered on PROSPERO (Registration ID: CRD42024518145).
抗菌药物耐药(AMR)细菌感染是对医疗保健系统的重大全球威胁。铜绿假单胞菌是医疗环境中的主要感染病原体之一,由于 AMR,现在是主要威胁之一。为了根据当地信息管理感染,有必要全面了解 AMR 的严重程度,特别是像铜绿假单胞菌这样的高度公共卫生重要病原体。
本系统评价和荟萃分析旨在确定铜绿假单胞菌的全国性 AMR 情况。
系统检索了从 2015 年至 2023 年 12 月 31 日期间 PubMed、Scopus、Web of Science、ScienceDirect 电子数据库、Google Scholar 搜索引擎和存储库注册机构的文章,以检索有关铜绿假单胞菌 AMR 的重要数据。对 23 项研究进行了系统综述和分析,以确定来自与医疗保健相关的感染的铜绿假单胞菌全国性 AMR 概况。从 10 种不同抗生素中提取铜绿假单胞菌的 AMR 数据,分别输入 Microsoft Excel 并使用 STATA 17.0 进行分析。计算科恩氏 kappa 以确定审稿人之间的一致性,使用方差倒数(I2)评估研究之间的异质性,并使用 Egger 检验识别发表偏倚。使用随机效应模型确定每种抗生素的总体耐药率。按感染类型和发表年份进行亚组分析。
本系统评价和荟萃分析显示,与医院获得性感染相关的临床标本中铜绿假单胞菌的总患病率为 4.38%(95%CI:3.00-5.76)。不同抗生素的铜绿假单胞菌 AMR 总患病率不同,阿米卡星为 20.9%(95%CI:6.2-35.8),头孢曲松为 98.72%(95%CI:96.39-101.4)。头孢曲松(98.72%)、磺胺甲恶唑-甲氧苄啶(75.41%)和阿莫西林-克拉维酸(91.2%)的耐药率较高。相反,阿米卡星(20.9%)和美罗培南(28.64%)的 AMR 相对较低。铜绿假单胞菌的多药耐药性(MDR)总发生率为 80.5%(95%CI:66.25-93.84)。按感染类型和发表年份进行亚组分析,与混合类型的医院获得性感染和手术部位感染相比,从与医疗保健相关的感染中分离出的铜绿假单胞菌对头孢他啶的耐药性更高(94.72%和 70.84%和 57.84%)。庆大霉素的抗菌药物耐药性在 2018-2020 年期间较高(73.96%),而在 2021-2023 年期间(42.69%)和 2015-2017 年期间(29.82%)较低。
本系统评价和荟萃分析显示出显著的高 AMR 和 MDR。从本系统评价和荟萃分析中获得的 AMR 情况敦促我们需要加强感染控制、抗菌药物管理实践和加强监测系统,以控制 AMR 的传播并确保有效治疗铜绿假单胞菌感染。
本系统评价和荟萃分析已在 PROSPERO(注册号:CRD42024518145)上注册。